Aim: While the European Union (EU) has approved several COVID-19 vaccines, new variants of concern may be able to escape immunity. The purpose of this study is to project the cost-effectiveness of future lockdown policies in conjunction with a variant-adapted vaccine booster. The exemplary scenario foresees a 25% decline in the vaccine protection against severe disease. Methods: A decision model was constructed using, for example, information on age-specific fatality rates, intensive care unit (ICU) costs and outcomes, and herd protection threshold. The costs and benefits of a future lockdown strategy were determined from a societal viewpoint under three future scenarios—a booster shot’s efficacy of 0%, 50%, and 95%. Results: The cost-effectiveness ratio of a lockdown policy in conjunction with a booster dose with 95% efficacy is €44,214 per life year gained. A lockdown is cost-effective when the probability of approving a booster dose with 95% efficacy is at least 48% (76% when considering uncertainty in input factors). Conclusion: In this exemplary scenario, a future lockdown policy appears to be cost-effective if the probability of approving a variant-adapted vaccine booster with an efficacy of 95% is at least 48%.
WangerSWeberE. Schul- und Kitaschließungen, Krankheit, Quarantäne – die coronabedingten Arbeitsausfälle der Erwerbstätigen steigen auf 59,2 Millionen Arbeitstage. IAB-Forum2021.
DaumannFFollertFGleißnerW, et al. Political decision making in the COVID-19 pandemic: the case of Germany from the perspective of risk management. Int J Environ Res Public Health2021; 19(1): 397.
9.
KhouryDSCromerDReynaldiA, et al.Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med2021; 27: 1205.
10.
DysonLHillEMMooreS, et al.Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. medRxiv. 2021.
GandjourA. The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. Q Rev Econ Finance. In print.
15.
WuZMcGooganJM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA2020; 323(13): 1239–1242.
FakhruddinBSBlanchardKRagupathyD. Are we there yet? The transition from response to recovery for the COVID-19 pandemic. Prog Disaster Sci2020; 7: 100102.
18.
PollockAMRoderickPChengKK, et al.Covid-19: why is the UK government ignoring WHO's advice?BMJ2020; 368: m1284.
GandjourA. How many intensive care beds are justifiable for hospital pandemic preparedness? A cost-effectiveness analysis for COVID-19 in Germany. Appl Health Econ Health Policy2021; 19(2): 181–190.
21.
GarrisonLPJrMansleyECAbbottTA3rd, et al.Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report--part II. Value Health. 2010; 13(1):8–13.
GailMBenichouJ. Encyclopedia of epidemiologic methods. Wiley reference series in biostatistics. Chichester: John Wiley & Sons, 2000.
24.
PréziosiMPHalloranME. Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis2003; 37(6): 772–779.
25.
ChowellGHaymanJMBettencourtLM, et al.Mathematical and statistical estimation approaches in epidemiology. Dordrecht, Heidelberg, London, New York: Springer, 2009.
26.
HurwiczL. The generalized bayes minimax principle: a criterion for decision making under uncertainty. Cowles Commission Discussion Paper 355. 1951.
27.
DenoeuxT. Decision-making with belief functions: a review. Int J Approximate Reason2019; 109: 87–110.
AumSLeeSYShinY. COVID-19 doesn’t need lockdowns to destroy jobs: the effect of local outbreaks in Korea. NBER Working Paper No. 27264. Cambridge, MA, 2020.
30.
SheridanAAndersenALHansenET, et al.Social distancing laws cause only small losses of economic activity during the COVID-19 pandemic in Scandinavia. Proc Natl Acad Sci U S A2020; 117(34): 20468–20473.
WongCHSiahKWLoAW. Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics. medRxiv, 2020.
34.
DimpflTSönksenJBechmannI, et al.Estimation of the SARS-CoV-2 infection fatality rate in Germany. medRxiv. 2021.
35.
ChallenRBrooks-PollockEReadJM, et al.Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ2021; 372: n579.
RamseyFP. A mathematical theory of saving. The Econ J1928; 38(152): 543–559.
39.
JohnJKoerberFSchadM. Differential discounting in the economic evaluation of healthcare programs. Cost Eff Resour Alloc2019; 17: 29.
40.
Abele-BrehmADreierHFuestC, et al.Die Bekämpfung der CORONAVIRUS-PANDEMIE tragfähig gestalten: EMPFEHLUNGEN für eine flexible, risikoadaptierte Strategie. 2020.
41.
NeedhamDMDinglasVDBienvenuOJ, et al.One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial. BMJ2013; 346: f1532.
Van Der Feltz-CornelisCMVarleyDAllgarVL, et al.Workplace stress, presenteeism, absenteeism, and resilience amongst university staff and students in the COVID-19 lockdown. Front Psychiatry2020; 11: 588803.
Federal Office of Statistics. Allgemeine Sterbetafel 2016/2018. Wiesbaden: Federal Office of Statistics, 2019.
55.
Federal Office of Statistics. Vorausberechneter Bevölkerungsstand. Moderate Entwicklung der Geburtenhäufigkeit, Lebenserwartung und Wanderung (G2L2W2). Federal Office of Statistics, 2000.
TwohigKANybergTZaidiA, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis2022; 22(1): 35–42.
58.
AbersMSMusherDM. Clinical prediction rules in community-acquired pneumonia: lies, damn lies and statistics. QJM2014; 107(7): 595–596.
59.
DamuthEMitchellJABartockJL, et al.Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis. Lancet Respir Med2015; 3(7): 544–553.
